Category Psoriasis

Risankizumab (SKYRIZI) — Drug Profile | TrialistMD TRIALISTMD.COM DRUG PROFILE IL-23 Antagonist · Humanized IgG1 mAb · Dermatology Risankizumab SKYRIZI™ · AbbVie Inc. Humanized IgG1 monoclonal antibody that selectively binds the p19 subunit of IL-23, blocking its interaction with the…

Brodalumab (SILIQ) — Drug Profile | TrialistMD TRIALISTMD.COM DRUG PROFILE IL-17RA Antagonist · Human Monoclonal Antibody IgG2κ · Dermatology brodalumab SILIQ™ · Valeant Pharmaceuticals North America LLC Fully human IgG2κ monoclonal antibody that selectively binds to interleukin-17 receptor A (IL-17RA),…

Tildrakizumab (ILUMYA) — Drug Profile | TrialistMD TRIALISTMD.COM DRUG PROFILE IL-23 Antagonist · Humanized mAb · Dermatology · BLA 761067 tildrakizumab ILUMYA™ · tildrakizumab-asmn · Merck Sharp & Dohme Corp. Humanized IgG1/κ monoclonal antibody selectively binding the p19 subunit of…

Guselkumab (TREMFYA) — Drug Profile | TrialistMD TRIALISTMD.COM DRUG PROFILE IL-23 p19 Inhibitor · Monoclonal Antibody · Dermatology Guselkumab TREMFYA™ · Janssen Biotech, Inc. Human IgG1λ monoclonal antibody selectively binding the p19 subunit of IL-23, preventing IL-23/IL-23R interaction and downstream…

crisaborole (EUCRISA) — Drug Profile | TrialistMD TRIALISTMD.COM DERMATOLOGY · PDE-4 INHIBITOR PDE-4 Inhibitor · Topical Small Molecule · Atopic Dermatitis · NDA 207695 crisaborole EUCRISA™ · Anacor Pharmaceuticals (Pfizer) First-in-class boron-based topical phosphodiesterase-4 (PDE-4) inhibitor. Inhibits cAMP degradation in…

Tapinarof (VTAMA) — Drug Profile | TrialistMD TRIALISTMD.COM DRUG PROFILE AhR Agonist · Small Molecule · Dermatology · Plaque Psoriasis Tapinarof VTAMA™  ·  Dermavant Sciences Inc. Tapinarof is a first-in-class aryl hydrocarbon receptor (AhR) agonist for topical use. Applied once…

Deucravacitinib (SOTYKTU) — Drug Profile | TrialistMD TRIALISTMD.COM DRUG PROFILE TYK2 Inhibitor · Dermatology · Plaque Psoriasis Deucravacitinib SOTYKTU™  ·  Bristol-Myers Squibb Company The world’s first tyrosine kinase 2 (TYK2) inhibitor approved for any indication. Deucravacitinib binds selectively to the…

spesolimab (SPEVIGO) — Drug Profile | TrialistMD TRIALISTMD.COM DRUG PROFILE IL-36R Antagonist · Humanized mIgG1 · Dermatology Spesolimab SPEVIGO®  ·  Boehringer Ingelheim Pharmaceuticals, Inc. The first and only FDA-approved interleukin-36 receptor (IL-36R) antagonist — and the first therapy specifically approved…

Bimekizumab (BIMZELX) — Drug Profile | TrialistMD TRIALISTMD.COM DRUG PROFILE IL-17A & IL-17F Inhibitor · IgG1 Monoclonal Antibody · Dermatology Bimekizumab BIMZELX® · UCB, Inc. A humanized IgG1 monoclonal antibody that selectively inhibits both IL-17A and IL-17F — the first…